Day One Biopharmaceuticals, Inc. (DAWN) Reports In-Line Q2 EPS
Tweet
Share
E-mailGet Alerts DAWN Hot Sheet
Join SI Premium – FREE
Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) reported Q2 EPS of ($0.61), in-line with the analyst estimate of ($0.61).
For earnings history and earnings-related data on Day One Biopharmaceuticals, Inc. (DAWN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
- LogicBio Therapeutics (LOGC) Misses Q2 EPS by 10c
- 4D Molecular Therapeutics, Inc. (FDMT) Misses Q2 EPS by 3c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
